Could a common steroid prevent a deadly complication in AIDS patients?

NCT ID NCT07565623

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a short course of the steroid prednisolone can prevent paradoxical immune reconstitution inflammatory syndrome (IRIS) in people with AIDS who have low CD4 counts and are starting HIV treatment. About 131 participants will receive either prednisolone or no extra treatment and be followed for 12 weeks. The goal is to see if the steroid reduces the risk of this serious inflammatory reaction.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Prednisolone
What this could lead to
If successful, this could provide a simple, short-term steroid treatment to prevent a dangerous inflammatory complication in people with AIDS starting HIV therapy.
What could go wrong
This is an early-stage trial with only 131 participants, and steroids have known side effects like increased infection risk. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CMV RETINITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.